問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Dermatology

Taipei Chang Gung Medical Foundation

Division of Dermatology

更新時間:2023-09-19

胡倩婷Hu, Chien-Ting
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月
  • s12345@cgmh.org.tw

篩選

List

3Cases

2025-03-01 - 2027-08-31

Phase II

Active
A Phase 2, multicenter, multiple-dose, monotherapy study to evaluate the safety of OBI-858 in participants with moderate to severe glabellar lines.
  • Condition/Disease

    Moderate to severe glabellar lines

  • Test Drug

    OBI-858

Participate Sites
5Sites

Recruiting5Sites

2025-11-03 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2017-01-01 - 2018-06-30

Phase III

A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of NEURONOX® vs. BOTOX® in Patients with Moderate to Severe Glabellar Lines
  • Condition/Disease

    Patients with moderate to severe glabellar lines

  • Test Drug

    Neuronox® Inj. (Clostridium Botulinum Toxin A)

Participate Sites
4Sites

Terminated4Sites